Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

ClinicalTrials.gov ID: NCT05783622

Public ClinicalTrials.gov record NCT05783622. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 16, 2026, 8:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Multicenter, Phase 1/1b Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Study identification

NCT ID: NCT05783622
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Janux Therapeutics; Industry
Enrollment: 130 participants

Conditions and interventions

Conditions

Interventions

JANX008 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 100 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 18, 2023
Primary completion: Dec 31, 2025
Completion: Sep 30, 2027
Last update posted: Oct 13, 2025

2023 – 2027

United States locations

U.S. sites: 18
U.S. states: 12
U.S. cities: 18

Facility	City	State	ZIP	Site status
City of Hope Medical Center	Duarte	California	91010	Recruiting
University of California, Davis Comprehensive Cancer Center	Sacramento	California	95817	Recruiting
University of California San Diego Moores Cancer Center	San Diego	California	92093	Recruiting
Winship Cancer Institute, Emory University	Atlanta	Georgia	30308	Recruiting
University of Chicago Medical Center	Chicago	Illinois	60637	Recruiting
University of Michigan	Ann Arbor	Michigan	48109	Recruiting
Henry Ford Health System	Detroit	Michigan	48202	Recruiting
Washington University	St Louis	Missouri	63110	Recruiting
Laura and Isaac Perlmutter Cancer Center NYU Langone Health	New York	New York	10016	Recruiting
University of North Carolina at Chapel Hill	Chapel Hill	North Carolina	27599	Recruiting
The Christ Hospital Cancer Center	Cincinnati	Ohio	45219	Recruiting
Ohio State University Hospital	Columbus	Ohio	43210	Recruiting
University of Pennsylvania, Abramson Cancer Center	Philadelphia	Pennsylvania	19104	Recruiting
UPMC Hillman Cancer Center	Pittsburgh	Pennsylvania	15232	Recruiting
Rhode Island Hospital	Providence	Rhode Island	02903	Recruiting
Sarah Cannon Research Institute	Nashville	Tennessee	37203	Recruiting
University of Texas Southwestern Medical Center	Dallas	Texas	75390	Recruiting
The University of Texas, MD Anderson Cancer Center	Houston	Texas	77030	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05783622, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 13, 2025 · Synced May 16, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05783622 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →